Skip to content

13F-HR filed by Opaleye Management Inc.

Opaleye Management Inc. filed this 13F-HR for the quarter ended 2017-12-31, filed 2018-02-09, with 35 holding rows worth $312,298,000.

Accession
0001493152-18-001743
Filed
2018-02-09
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2017

A holdings report, 35 entries on the cover page, a total value of $312,298,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $312,298,000 with VALUE read as thousands by filing date, 13F file number 028-15896. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AXOGEN INC05463X106COM1,970,000$55,751,000thousands by filing date
BLUEPRINT MEDICINES CORP09627Y109COM735,000$55,426,000thousands by filing date
FIBROGEN INC31572Q808COM360,000$17,064,000thousands by filing date
LOXO ONCOLOGY INC548862101COM176,300$14,841,000thousands by filing date
IMMUNOMEDICS INC452907108COM898,800$14,524,000thousands by filing date
CODEXIS INC192005106COM1,700,600$14,200,000thousands by filing date
XOMA ROYALTY CORPORATION98419J206COMMON STOCK320,200$11,399,000thousands by filing date
ABLYNX NV00372Y905SPONSORED ADR420,000$10,495,000thousands by filing date
CORIUM INTL INC21887L107COM1,060,000$10,186,000thousands by filing date
SANGAMO THERAPEUTICS INC800677106COM580,000$9,512,000thousands by filing date
STRONGBRIDGE BIOPHARMA PLCG85347105SHS USD1,250,000$9,062,000thousands by filing date
FENNEC PHARMACEUTICALS INC31447P100COMMON STOCK846,900$8,486,000thousands by filing date
AGIOS PHARMACEUTICALS INC00847X104COM130,000$7,432,000thousands by filing date
AUDENTES THERAPEUTICS INC.05070R104Common Stock210,000$6,652,000thousands by filing date
CRISPR THERAPEUTICS AG NAMEN AKTH17182108Stock281,000$6,597,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM665,000$6,118,000thousands by filing date
ARDELYX INC039697107COM900,000$5,940,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS960,000$5,769,000thousands by filing date
ARGENX SE SPONSORED ADR04016X101ADR88,500$5,587,000thousands by filing date
NEKTAR THERAPEUTICS640268108COM80,000$4,777,000thousands by filing date
Rocket Pharmaceuticals Inc45780V102SHS1,802,000$4,703,000thousands by filing date
ACCELERON PHARMA INC00434H108COM101,500$4,307,000thousands by filing date
ULTRAGENYX PHARMACEUTICAL IN90400D108COM90,000$4,174,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW860,000$3,448,000thousands by filing date
DERMIRA INC24983L104COM100,000$2,781,000thousands by filing date
CHIMERIX INC COM16934W106Stock600,000$2,778,000thousands by filing date
VIKING THERAPEUTICS INC92686J106COM480,558$1,951,000thousands by filing date
UNIQURE NVN90064101SHS90,801$1,778,000thousands by filing date
QUANTERIX CORP74766Q101COMMON STOCK65,000$1,395,000thousands by filing date
ACHILLION PHARMACEUTICALS IN00448Q201COM440,000$1,267,000thousands by filing date
PROTALIX BIOTHERAPEUTICS INC74365A101COM1,825,000$1,206,000thousands by filing date
RHYTHM PHARMACEUTICALS INC76243J105COM38,300$1,113,000thousands by filing date
SYROS PHARMACEUTICALS INC87184Q107COM74,074$720,000thousands by filing date
SPECTRUM PHARMACEUTICALS INC84763A108COM31,000$587,000thousands by filing date
BIOLINERX LTD-SPONS ADR09071M106SPON250,000$272,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001493152-18-001743this filing2018-02-09acceptance time not in the bulk data set